NO20060328L - Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser - Google Patents

Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser

Info

Publication number: NO20060328L
Authority: NO; Norway
Prior art keywords: acute; treatment; ache inhibitor; neurological disorders; combination
Prior art date: 2003-07-25

Application number

NO20060328A

Other languages

English (en)

Norwegian (no)

Inventor

Thomas Johannes Woltering

Erwin Goetschi

Theresa Maria Ballard

Silvia Gatti Mcarthur

Juergen Wichmann

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-25

Filing date

2006-01-20

Publication date

2006-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060328(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-20 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2006-02-17 Publication of NO20060328L publication Critical patent/NO20060328L/no

Links

102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title abstract 5
239000005557 antagonist Substances 0.000 title abstract 5
108010038421 metabotropic glutamate receptor 2 Proteins 0.000 title abstract 5
229940124596 AChE inhibitor Drugs 0.000 title abstract 4
208000012902 Nervous system disease Diseases 0.000 title abstract 2
208000025966 Neurological disease Diseases 0.000 title abstract 2
230000001154 acute effect Effects 0.000 title abstract 2
230000001684 chronic effect Effects 0.000 title abstract 2
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

NO20060328A 2003-07-25 2006-01-20 Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser NO20060328L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP03016968		2003-07-25
PCT/EP2004/008020 WO2005014002A1 (en)	2003-07-25	2004-07-17	Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders

Publications (1)

Publication Number	Publication Date
NO20060328L true NO20060328L (no)	2006-02-17

Family

ID=34130033

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060328A NO20060328L (no)	2003-07-25	2006-01-20	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser

Country Status (27)

Country	Link
US (1)	US7235547B2 (de)
EP (1)	EP1651234B1 (de)
JP (1)	JP5005343B2 (de)
KR (1)	KR100764330B1 (de)
CN (1)	CN1856312A (de)
AR (1)	AR045926A1 (de)
AT (1)	ATE374030T1 (de)
AU (1)	AU2004262897B9 (de)
BR (1)	BRPI0412919A (de)
CA (1)	CA2532347C (de)
CO (1)	CO5640124A2 (de)
DE (1)	DE602004009195T2 (de)
DK (1)	DK1651234T3 (de)
ES (1)	ES2293287T3 (de)
HR (1)	HRP20070552T3 (de)
IL (1)	IL173131A (de)
MX (1)	MXPA06000705A (de)
MY (1)	MY138394A (de)
NO (1)	NO20060328L (de)
NZ (1)	NZ544719A (de)
PL (1)	PL1651234T3 (de)
PT (1)	PT1651234E (de)
RU (1)	RU2357734C2 (de)
SI (1)	SI1651234T1 (de)
TW (1)	TW200524614A (de)
WO (1)	WO2005014002A1 (de)
ZA (1)	ZA200600693B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050222175A1 (en) *	2004-03-31	2005-10-06	Dhanoa Dale S	New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) *	2003-03-31	2009-11-03	Epix Delaware, Inc.	Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) *	2004-05-17	2009-02-10	Epix Delaware, Inc.	Thienopyridinone compounds and methods of treatment
US7576211B2 (en) *	2004-09-30	2009-08-18	Epix Delaware, Inc.	Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) *	2004-09-30	2009-10-06	Epix Delaware, Inc.	Compositions and methods for treating CNS disorders
US7407966B2 (en) *	2004-10-07	2008-08-05	Epix Delaware, Inc.	Thienopyridinone compounds and methods of treatment
EP2275096A3 (de)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (de)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (de)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenese mittels angiotensin-modulation
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
DE102008022221A1 (de) *	2008-05-06	2009-11-12	Universität des Saarlandes	Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010065743A2 (en) *	2008-12-03	2010-06-10	Nanotherapeutics, Inc.	Bicyclic compounds and methods of making and using same
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
US8541404B2 (en) *	2009-11-09	2013-09-24	Elexopharm Gmbh	Inhibitors of the human aldosterone synthase CYP11B2
RU2472475C2 (ru) *	2010-04-20	2013-01-20	Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ)	Способ комбинированного лечения глаукомной оптической нейропатии
HK1206615A1 (en)	2012-10-23	2016-01-15	霍夫曼-拉罗奇有限公司	Mglu2/3 antagonists for the treatment of autistic disorders
MX2016013711A (es)	2014-04-23	2017-01-13	Hoffmann La Roche	Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
CN112462047B (zh) *	2020-11-13	2023-02-07	北京元恩生物技术有限公司	一种尼卡巴嗪检测试剂盒及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
FI95572C (fi) *	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DE69911603T2 (de) *	1998-06-22	2004-07-29	Neurosearch A/S	Synthese von 5- oder 8-bromoisoquinolin derivaten
US6194403B1 (en) *	1999-09-09	2001-02-27	Unitech Pharmaceuticals, Inc.	Tacrine derivatives for treating Alzheimer's disease
TR200201023T2 (tr) *	1999-10-15	2002-09-23	F. Hoffmann-La Roche Ag	Benzodiazepin türevleri.
AU779874B2 (en) *	1999-10-15	2005-02-17	F. Hoffmann-La Roche Ag	Benzodiazepine derivatives
CA2310926C (en) *	2000-04-03	2002-10-15	Janssen Pharmaceutica N.V.	A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
EP1203584A1 (de)	2000-10-13	2002-05-08	M.D.M. S.r.l.	Cholinerger Vorläufer (insbesondere Cholin-alfoscerat) assoziiert mit einem Acetylcholinesterase Inhibitor (wie z.B. Rivastigmin, Donepezil)
US6500972B2 (en) *	2001-01-03	2002-12-31	Chinese Petroleim Corp.	Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts
US6500955B1 (en) *	2001-02-02	2002-12-31	National Institute Of Pharmaceutical Education And Research	One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate
EP1377640B1 (de) *	2001-04-09	2017-05-17	FUJIFILM Corporation	Azoverbindungen und verfahren zur herstellung derselben und neue zwischenverbdindungen zur herstellung von azoverbindungen
HRP20030791B1 (en) *	2001-04-12	2006-06-30	F. Hoffmann - La Roche Ag	DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS mGluR2 ANTAGONISTS I
EP1379511B1 (de) *	2001-04-12	2005-07-20	F. Hoffmann-La Roche Ag	DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
US6949542B2 (en) *	2002-02-06	2005-09-27	Hoffman-La Roche Inc.	Dihydro-benzo[b][1,4]diazepin-2-one derivatives

2004
- 2004-07-17 PL PL04741126T patent/PL1651234T3/pl unknown
- 2004-07-17 AT AT04741126T patent/ATE374030T1/de active
- 2004-07-17 WO PCT/EP2004/008020 patent/WO2005014002A1/en not_active Ceased
- 2004-07-17 AU AU2004262897A patent/AU2004262897B9/en not_active Ceased
- 2004-07-17 CN CNA2004800278083A patent/CN1856312A/zh active Pending
- 2004-07-17 NZ NZ544719A patent/NZ544719A/xx unknown
- 2004-07-17 SI SI200430524T patent/SI1651234T1/sl unknown
- 2004-07-17 ES ES04741126T patent/ES2293287T3/es not_active Expired - Lifetime
- 2004-07-17 MX MXPA06000705A patent/MXPA06000705A/es active IP Right Grant
- 2004-07-17 JP JP2006521458A patent/JP5005343B2/ja not_active Expired - Fee Related
- 2004-07-17 DE DE602004009195T patent/DE602004009195T2/de not_active Expired - Lifetime
- 2004-07-17 HR HR20070552T patent/HRP20070552T3/xx unknown
- 2004-07-17 BR BRPI0412919-9A patent/BRPI0412919A/pt not_active Application Discontinuation
- 2004-07-17 PT PT04741126T patent/PT1651234E/pt unknown
- 2004-07-17 RU RU2006105721/15A patent/RU2357734C2/ru not_active IP Right Cessation
- 2004-07-17 DK DK04741126T patent/DK1651234T3/da active
- 2004-07-17 CA CA2532347A patent/CA2532347C/en not_active Expired - Fee Related
- 2004-07-17 KR KR1020067001762A patent/KR100764330B1/ko not_active Expired - Fee Related
- 2004-07-17 EP EP04741126A patent/EP1651234B1/de not_active Expired - Lifetime
- 2004-07-21 TW TW093121764A patent/TW200524614A/zh unknown
- 2004-07-22 US US10/896,494 patent/US7235547B2/en not_active Expired - Fee Related
- 2004-07-22 AR ARP040102592A patent/AR045926A1/es not_active Application Discontinuation
- 2004-07-23 MY MYPI20042981A patent/MY138394A/en unknown
2006
- 2006-01-12 IL IL173131A patent/IL173131A/en not_active IP Right Cessation
- 2006-01-20 NO NO20060328A patent/NO20060328L/no not_active Application Discontinuation
- 2006-01-24 ZA ZA200600693A patent/ZA200600693B/en unknown
- 2006-01-24 CO CO06006378A patent/CO5640124A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1651234B1 (de)	2007-09-26
SI1651234T1 (sl)	2008-02-29
CN1856312A (zh)	2006-11-01
KR100764330B1 (ko)	2007-10-05
DE602004009195T2 (de)	2008-06-26
RU2357734C2 (ru)	2009-06-10
AU2004262897B9 (en)	2009-12-17
DE602004009195D1 (de)	2007-11-08
PL1651234T3 (pl)	2008-02-29
US7235547B2 (en)	2007-06-26
RU2006105721A (ru)	2007-09-10
HRP20070552T3 (en)	2008-05-31
DK1651234T3 (da)	2008-01-28
IL173131A0 (en)	2006-06-11
AU2004262897A1 (en)	2005-02-17
AU2004262897B2 (en)	2009-08-20
PT1651234E (pt)	2007-12-28
NZ544719A (en)	2009-04-30
ATE374030T1 (de)	2007-10-15
TW200524614A (en)	2005-08-01
AR045926A1 (es)	2005-11-16
US20050049243A1 (en)	2005-03-03
JP2007504096A (ja)	2007-03-01
MXPA06000705A (es)	2006-04-11
KR20060037404A (ko)	2006-05-03
IL173131A (en)	2010-12-30
WO2005014002A1 (en)	2005-02-17
ZA200600693B (en)	2007-05-30
CA2532347C (en)	2012-03-27
MY138394A (en)	2009-05-29
BRPI0412919A (pt)	2006-09-26
EP1651234A1 (de)	2006-05-03
ES2293287T3 (es)	2008-03-16
CO5640124A2 (es)	2006-05-31
JP5005343B2 (ja)	2012-08-22
CA2532347A1 (en)	2005-02-17

Legal Events

Date	Code	Title	Description
2011-02-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
MXPA06000705A (es)	2006-04-11	Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
BRPI0411825A (pt)	2006-08-08	inibidores de p38 quinase a base de heterociclo de 5 elementos
BRPI0516132A (pt)	2007-12-04	compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica
BRPI0407993A (pt)	2006-03-07	inibidores de p38 e métodos para uso dos mesmos
CY1112238T1 (el)	2015-12-09	Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
WO2006047516A3 (en)	2006-10-12	Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20034549L (no)	2003-10-09	Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
CY1108725T1 (el)	2014-04-09	Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
WO2004071431A3 (en)	2004-12-02	Method and composition for treating neurodegenerative disorders
MX2007002311A (es)	2008-03-10	Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
DE60234616D1 (de)	2010-01-14	Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE554084T1 (de)	2012-05-15	N-hydroxyacrylamidverbindungen
WO2005084654A3 (en)	2005-11-17	Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
MXPA05004621A (es)	2005-06-08	Derivados de anilinopirazol utiles en el tratamiento de la diabetes.
WO2006074265A3 (en)	2007-06-14	Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
BRPI0411864A (pt)	2006-08-08	combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
WO2007044325A3 (en)	2007-09-27	Apoe4 domain interaction inhibitors and methods of use thereof
NO20073610L (no)	2007-09-12	Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
DK1784173T3 (da)	2012-05-07	Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
AR020740A1 (es)	2002-05-29	Composicion y metodo para tratar enfermedades alergicas
MX2008001608A (es)	2008-04-14	Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
TW200621261A (en)	2006-07-01	Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
DK1503764T3 (da)	2010-05-10	5-HT4-receptor-antagonister til behandling af hjertesvigt
IL175358A0 (en)	2006-09-05	1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
MXPA01009032A (es)	2004-11-10	Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso se la produccion de il-12.